158 results about "Colon tissue" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of extracellular vesicle-like particles derived from divaricate saposhnikovia roots in preparation of medicines for preventing and treating intestinal diseases. Research on the physiological efficacy of the extracellular vesicle-like particles from divaricate saposhnikovia root shows that the extracellular vesicle-like particles can relieve colon shortening and colon tissue damage caused by dextran sodium sulfate, relieve intestinal inflammation and promote repair of intestinal barriers including mechanical barriers, chemical barriers and immune barriers. The polypeptide has potential for preparing the medicine for treating the intestinal diseases, and a new strategy is provided for preventing or treating the intestinal diseases.

The invention relates to the field of new application of traditional Chinese medicinal materials, and particularly provides application of ash grass root in preparation of medicine for treating ulcerative colitis, DSS-induced mouse colitis model experiments and UC patient control experiments show that ash grass root has remarkable technical effects in treatment of ulcerative colitis, and the application of ash grass root in preparation of medicine for treating ulcerative colitis in preparation of medicine for treating ulcerative colitis in preparation of medicine for treating ulcerative colitis. The gray couchgrass root shows the effect of relieving inflammatory response, tissue damage and immune disorder related to colitis; the intestinal mucosa repair is promoted; the intestinal barrier function is strengthened; the pathological state of colon tissue is improved; the level of inflammatory factors is reduced; and flora metabolism can be adjusted. The invention provides a new natural medicine source for preventing and treating ulcerative colitis, and has good application value and industrial transformation prospect.

The invention relates to an establishment method and application of in-vitro intestinal inflammation models of mice of different ages, and relates to the technical field of biology. According to the invention, young, adult, middle-aged and old wild type (WT) and TLR4 gene deletion type (TLR4 <- / ->) mice are selected, colon tissues are cultured in vitro, inflammatory response is induced by using interleukin-1beta (IL-1beta) stimulation, an age-related intestinal inflammation model is constructed, the inflammation phenotype of the mouse model and the activity of a TLR4 / MyD88 / NF-kappa B signaling pathway are determined by comparing WT and TLR4 <- / ->, and the age-related intestinal inflammation model is constructed. The core function of the TLR4 in regulating age-dependent intestinal barrier dysfunction is defined, a regulatory network of the TLR4 in intestinal immune aging and flora-host interaction is disclosed, and an age personalized medical strategy is promoted. According to the invention, an efficient and customizable multi-age in-vitro intestinal inflammation model is constructed, and an innovative platform is provided for mechanism analysis and intervention drug screening of TLR4 targeted therapy and age-related intestinal diseases.

The invention discloses a novel application of bifidobacterium breve CCFM1078 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium breve CCFM1078 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mastocyte infiltration is reduced; (2) the relative expression quantity of mRNA (messenger Ribonucleic Acid) of mouse skin barrier function related genes is increased; (3) reducing the total IgE level of mouse serum; (4) reducing the levels of IL-4, IL-13 and TSLP in mouse skin tissues, improving the levels of IL-10 and IFN-gamma, recovering Th1 / Th2 immune balance, and maintaining immune homeostasis; (5) activating the expression of AHR and CYP1A1 in the skin tissue of the mouse; (6) improving IgA and sIgA secretion of mouse colon tissue; and (7) compared with a representative high-yield ILA strain, the ILA yield is higher.

The invention relates to the technical field of microorganisms, in particular to lactobacillus plantarum, selenium-rich lactobacillus plantarum and application thereof. The lactobacillus plantarum with the preservation number of GDMCC No: 64006 is provided, selenium is enriched through the lactobacillus plantarum, and inorganic selenium is converted into biological nano-selenium which can be preserved in vivo for a longer time. The invention provides a technical scheme that lactobacillus plantarum is subjected to selenium-enriched culture to prepare the selenium-enriched lactobacillus plantarum, the elimination capability of the prepared selenium-enriched lactobacillus plantarum to free radicals DPPH and ABTS < + > and the endurance capability of the prepared selenium-enriched lactobacillus plantarum to simulated gastric juice can be remarkably improved, and the tolerance of the prepared selenium-enriched lactobacillus plantarum to cholate and simulated artificial intestinal juice cannot be reduced; meanwhile, the AIEC associated colitis can be relieved from the aspects of accelerating weight recovery, reducing colon tissue pathological damage, reducing AIEC colonization, promoting intestinal barrier repair, reducing the proinflammatory factor level, improving the selenium level, improving intestinal flora disorder and the like.

The invention provides thesium chinense polysaccharide as well as a preparation method and application thereof, compared with the prior art, neutral polysaccharide TP1 is efficiently extracted from thesium chinense by adopting a hot water extraction method, the neutral polysaccharide TP1 mainly comprises fructose, glucose and galactose according to a molar ratio of 44.7: 33.8: 17.9, and the molecular weight Mw of the TP1 measured by adopting a GPC-RI-MALS chromatographic method is 5377Da. The invention also researches the protective effect of thesium chinense polysaccharide on DSS-induced colitis. The TP1 reduces the loss of intestinal tight junction proteins (Claudin-1, Occludin and ZO-1), regulates the abundance of bacteria in the intestinal tract and enriches bacteria (ruminococcus, lactobacillus and bifidobacterium) capable of generating SCFAs, in addition, the TP1 increases the expression of GPR41 and GPR43 receptors in colon tissues, and the symptoms of colitis are relieved by reducing oxidative stress and inflammatory cytokine levels through the GPR41 and GPR43 receptors mediated by the SCFAs. The thesium chinense polysaccharide TP1 prepared by the invention can be used for preparing medicines for preventing and treating colitis and also can be used for preparing food.

The present invention provides a kind of radix schizonepetae extract for treating ulcerative colitis and its preparation method and application, and relates to the field of biomedicine technology. The preparation method of the radix schizonepetae extract of the present invention comprises: soaking radix schizonepetae in water, heating and boiling, condensing and refluxing, filtering, and collecting the filtrate, which is the radix schizonepetae extract. The radix schizonepetae extract of the present invention can reduce collagen deposition and intestinal epithelial cell apoptosis in the colon epithelium of ulcerative colitis, has the effect of downregulating the abnormally high expression of genes and proteins such as N-cadherin, IntegrinA1, Vinculin, TGF-β2, Srcin, etc. in the colon tissue of ulcerative colitis, reduces colon fibrosis and inflammatory damage, protects the barrier function of the colon epithelium, and has the effect of inhibiting the overexpression of Wnt 5A / B and β-Catenin proteins caused by DSS, and alleviates colon fibrosis, thereby achieving the effect of treating ulcerative colitis and alleviating colon fibrosis.

The invention discloses application of fraxinellone as a cGAS-STING signal channel inhibitor in preparation of a medicine for treating inflammatory bowel disease, and belongs to the technical field of biological medicine. Aiming at the problem that the specific action mechanism between fraxinellone and the inflammatory bowel disease is not clear, the invention researches the specific action mechanism of fraxinellone for exerting the treatment and protection effects on the inflammatory bowel disease from the in-vivo and in-vitro aspects. Results show that the FRA can significantly inhibit the increase of the ROS level of IEC-6 cells caused by LPS, improve the mitochondrial membrane potential, significantly improve the pathological characteristics of DSS-induced mouse weight loss, DAI index increase, red, swollen and shortened colon, damaged colon tissue structure and the like, and inhibit the expression level of inflammatory factors. According to the present invention, it is found that the FRA can up-regulate the TJ tight junction protein and recover the intestinal barrier function by regulating the expression of cGAS-STING signal channel related proteins such as cGAS, STING, p-TBK1, NF-kappa B and the transcriptional level of mRNA, such that the IBD treatment effect is provided, and the basic basis is provided for the development of the new IBD treatment drug or strategy.

The present application relates to the technical field of small molecule medicines, in particular to a quinoline derivative compound or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition and application thereof. The quinoline derivative compound or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, the structural formula of the quinoline derivative compound is shown in the following formula I or formula II: formula I and formula II, the quinoline derivative compound has a significant improvement effect on symptoms such as ulceration and inflammation of colon tissue, and can effectively treat inflammatory bowel disease.

The present invention discloses a method for determining the content of organic acid metabolites of black plum in colon tissue and its application. The determination method comprises the following steps: (1) adding sterile physiological saline to the colon tissue, grinding, adding methanol to continue grinding, centrifuging, collecting the supernatant, adding methanol and vortexing, centrifuging, and finally adding water and vortexing to obtain a sample solution to be tested; (2) using high performance liquid chromatography-mass spectrometry to draw standard curves of the three organic acids using citric acid, malic acid, and quinic acid standards, wherein citric acid is used in positive ion mode, and malic acid and quinic acid are used in negative ion mode; (3) using the same method to detect the sample to be tested, and the concentration or content of the three organic acid metabolites (citric acid, malic acid, and quinic acid) can be calculated based on the standard curve. The method of the present invention is simple and highly sensitive and can be used to study the mechanism of the effect of black plum on ulcerative colitis.

The invention belongs to the technical field of biology, and discloses a preparation method of an intestinal plexus patch, which comprises the following steps: killing an intestinal tract donor, fixing intestinal tissue segments of duodenum, jejunum, ileum or colon by using paraformaldehyde, and dehydrating to obtain dehydrated intestinal tissue segments; washing the dehydrated intestinal tissue section and removing mesentery, fat and Pari's lymph nodes attached to the jejunum, cutting an intestinal mass of about 4-6mm perpendicular to the intestinal tissue section, flatly laying the intestinal mass on a glass slide, dropwise adding a PBS (Phosphate Buffer Solution) of Triton X-100, fixing the intestinal mass by using a smooth surface of a pair of tweezers, stripping muscle tissues along the annular muscle direction, and drying the intestinal mass in a drying oven. The intestinal slices with intermuscular nerve plexus are obtained; finally, the intestinal piece with the intermuscular nerve plexus is cleaned, then fluorescent staining and piece sealing are conducted, and the mouse intestinal nerve plexus patch is obtained. The preparation method of the mouse intestinal nerve plexus patch has the advantages of being convenient, rapid and the like.

The invention discloses a rhamnosus lactobacillus QS001 and a use thereof for preparing an intestinal probiotic preparation, wherein the rhamnosus lactobacillus QS001 is classified and named as rhamnosus lactobacillus Lacticaseibacillus rhamnosus , deposited in the General Microbiology Center of China Microorganism Culture Collection Committee, with the deposit number CGMCC No.29275. The rhamnosus casei bacteria QS001 is used in the preparation of intestinal probiotic preparations. The active ingredients of the probiotic preparations include the bacteria of the above-mentioned rhamnosus casei bacteria QS001. The rhamnosus casei bacteria QS001 is also used in the preparation of immune disorder regulators, drugs for increasing the concentration of anti-inflammatory cytokines and / or reducing the concentration of pro-inflammatory cytokines in colon tissue, and has the advantage of alleviating or treating inflammatory bowel disease and regulating immune disorders.

The application discloses an application of Bacteroides intestinalis in preventing and / or treating ulcerative colitis and belongs to the field of biopharmacy. The application claims the use of Bacteroides intestinalis in preparing a medicine or a composition for preventing and / or treating ulcerative colitis. It is found that Bacteroides intestinalis can significantly inhibit the weight loss of a mouse model of ulcerative colitis, reduce a disease activity index, repair colon tissue damage, and down-regulate the expression level of a proinflammatory factor of the organism, and thus has a clear preventive and / or therapeutic effect on ulcerative colitis and has a good clinical transformation application prospect. Therefore, the Bacteroides intestinalis has a prospect of being developed into a medicine or a composition for preventing and / or treating ulcerative colitis.

The invention belongs to the technical field of microorganisms, and discloses clostridium butyricum ML5358 and application thereof.The clostridium butyricum ML5358 provided by the invention has the preservation number of CGMCC No.37000. The strain can effectively relieve mouse colitis induced by DSS and remarkably reduce expression of colon tissue inflammatory factors Il-6 and Il-1beta, and the preservation number of the clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. In addition, skeletal muscle lipid metabolism can be regulated and controlled through the intestine-muscle axis, expression of fat synthesis and uptake related genes Srebf1, Acc1 and Fabp4 is specifically up-regulated, the content of intramuscular triglyceride is remarkably increased, and intramuscular fat deposition is promoted. According to the clostridium butyricum ML5358 and the application thereof, the functional limitation of traditional clostridium butyricum is broken through, and a new strain resource is provided for developing a novel microbial preparation or a feed additive capable of improving intestinal health and improving livestock and poultry meat quality.

The invention provides an application of a heat shock protein 90 inhibitor in preparation of a medicine for treating intestinal injury and complicated intestinal inflammation thereof. The HSP90 inhibitor is suitable for treating colon tissue injury caused by a medicine for inducing Gasdermin E (GSDME) mediated pyroptosis. The HSP90 inhibitor specifically inhibits the expression of GSDME protein in normal intestinal epithelial cells and reduces the sensitivity of the normal intestinal epithelial cells to drug-induced GSDME-mediated pyroptosis, so that the damage to colon tissues is relieved, and the induced inflammatory response of the colon tissues is effectively inhibited. TAS-116 and BIIB021 are used as representative drugs of the HSP90 inhibitor, 4 mg / kg of TAS-116 and BIIB021 are used for a mouse colon injury model constructed by 5-FU and CDDP, and the result shows that the HSP90 inhibitor can obviously improve weight loss and colon tissue injury of mice caused by the drugs, and has a good application prospect. Therefore, the HSP90 inhibitor has remarkable curative effect and application value in the aspect of relieving or preventing and treating intestinal injury caused by drugs.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to chlorogenic acid temperature-sensitive sol, a preparation method and application thereof, chlorogenic acid gel and application thereof. According to the chlorogenic acid temperature-sensitive sol provided by the invention, the chlorogenic acid with anti-inflammatory activity is combined with a temperature-sensitive material for the first time to construct a temperature response type in-situ gel delivery system. The chlorogenic acid temperature-sensitive sol provided by the invention is in a flowable sol state at room temperature, and is convenient for administration in a liquid form through an injector or an enema device; when the temperature-sensitive material is in contact with a human body cavity mucous membrane, the temperature-sensitive material triggers sol-gel phase change through an intermolecular hydrophobic effect to form semi-solid three-dimensional mesh gel which is tightly adhered to the surface of the mucous membrane, so that positioned enrichment and long-acting slow release of a medicine in a focus area are realized, the symptoms of ulcerative colitis are relieved, and the disease activity index is reduced; the colon length shortening and the pathological injury of colon tissues are improved, the technical defects of non-uniform distribution, short enema retention time and the like of the traditional suppository are overcome, and the colon suppository has clinical application potential.

The invention discloses a compound with an anti-inflammatory effect in Enshi Sichuan amur corktree, separation and application, and belongs to the technical field of medicines. The invention particularly discloses a compound which is separated from Enshi chuan amur corktree and has an anti-inflammatory effect, a separation preparation method and application. Researches prove that the compound has an inhibition effect on the expression of inflammatory factors IL-1beta and IL-17A, can inhibit the generation and secretion of an inflammatory factor IL-6 in Th17 cells, can reduce the expression level of Caspase-1 and NLRP3 proteins in colon tissues of mice, and can reduce the inflammatory response of ulcerative colitis of DSS modeling mice in a dose-dependent manner. The compound (limonin compound) with the anti-inflammatory effect in Enshi Huangchuan amur corktree can be used as a lead compound for development of anti-inflammatory drugs, and is of great significance to comprehensive utilization and development of Enshi Huangchuan amur corktree.

A Lacticaseibacillus rhamnosus MBP01 and a combination thereof for preventing and treating irritable bowel syndrome are provided, which relates to the technical field of microorganism. A deposit number of the Lacticaseibacillus rhamnosus MBP01 is GDMCC NO: 64725. The MBP01 can improve a weight loss trend of IBS model mice, increase food intake and feces water content, alleviate colon tissue damage, downregulate expression levels of IL-1β, TNF-α, PAR-2, and serum CORT and increase an expression level of IL-10. MBP01 with a high concentration can improve an expression level of OCC. Therefore, MBP01 has a certain positive regulatory effect on the intestinal function of IBS model mice and can effectively prevent and treat irritable bowel syndrome.

The present application relates to a new use of halogenophenol compound 4,5,2'-trihydroxy-2,5'-dibromobenzophenone, in particular in the preparation of a drug for treating inflammatory bowel disease. The halogenophenol compound of the present application can significantly alleviate the weight loss and colon shortening of the colonitis model, reduce the disease activity index of the colonitis model, reduce the inflammatory cell infiltration of the colonitis model, reduce the expression of inflammatory factors, has an immune regulation function on the intestinal tract, and is superior to the clinical first-line drug mesalazine in most indicators, and has application prospects in the treatment of inflammatory bowel disease.

The invention relates to the technical field of intestinal inflammation disease prevention and treatment, in particular to a polypeptide for treating ulcerative colitis. The polypeptide provided by the invention is an active heptapeptide derived from natural protein, and has a clear chemical structure and a repeatable preparation process. Research results show that the polypeptide can significantly improve symptoms of mouse ulcerative colitis induced by dextran sodium sulfate (DSS), including weight loss reduction, disease activity index (DAI) reduction, colon length recovery, colon tissue pathological damage improvement and inflammation-related signal pathway inhibition, so that the improvement effect of the polypeptide on intestinal inflammation is verified. The polypeptide is prepared into a pharmaceutical composition or health-care food, so that the comprehensive effects of considering prevention and treatment and simultaneously improving inflammation and repairing barriers can be realized, and a new strategy and a material basis are provided for preventing and treating ulcerative colitis and other intestinal inflammatory diseases.

This invention discloses the application of chestnut total burr ethanol extract in the preparation of anti-colitis drugs. In this invention, the chestnut total burr ethanol extract with anti-colitis properties is obtained by extracting chestnut total burrs with 70% ethanol. This chestnut total burr ethanol extract inhibits the production of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) without cytotoxicity; it has a significant inhibitory effect on dextran sulfate sodium-induced colitis in mice, including slowing down weight loss, reducing mouse DAI scores, alleviating colonic tissue damage, downregulating the levels of IL-6, IL-1β, TNF-α, and MDA in mouse colonic tissue and serum, and enhancing the activities of CAT and SOD in mouse colonic tissue and serum. Therefore, the chestnut total burr ethanol extract has significant anti-inflammatory effects both in vivo and in vitro, and can be used to treat colitis.

Disclosed is the use of a hulless barley grass extract containing polyphenol in controlling colorectal cancer and ulcerative colitis. In terms of the ulcerative colitis, the drug ameliorates a weight loss of colitis mice, reduces an oxidative stress level of colitis mice, reduces relative mRNA expression levels of inflammatory factors TNF-α, IL-6, and IL-1β, and effectively improves a pathological damage caused by inflammatory response in the colon tissue of ulcerative colitis model mice. In terms of the colorectal cancer, the drug is shown to prevent and / or inhibit the occurrence and development of ulcerative colitis and associated colorectal cancer thereof by inhibiting the overexpression of a Wnt signaling pathway and reducing the inflammatory response and oxidative stress damage. The raw materials of the extract are derived from natural products, which are easy to collect and highly safe.

The invention discloses bifidobacterium longum CCFM1509 with autophagy promoting and colon aging resisting functions and application of the bifidobacterium longum CCFM1509, and belongs to the field of microorganisms. The bifidobacterium longum CCFM1509 provided by the invention can relieve colon tissue pathological damage caused by senescence, reduce the level of proinflammatory cytokines in colon tissues, reduce the oxidative stress level in the colon tissues, reduce the level of senescence-related senescence markers in the colon tissues and adjust the autophagy level in the colon tissues. Therefore, the bifidobacterium longum CCFM1509 disclosed by the invention can be widely applied to the field of medicines and is used for preparing pharmaceutical preparations for preventing or treating colon aging and related diseases; meanwhile, the bacillus subtilis can also be used for developing various functional fermented foods, health foods and formula foods for special medical purposes, provides a new microbial solution for promoting intestinal health and delaying colon senescence, and has important development value and wide market prospects.

The invention provides application of filter paper rumen clostridium to prevention and / or treatment of ulcerative colitis, and belongs to the technical field of microorganisms. The rumen clostridium capable of decomposing the filter paper, disclosed by the invention, is a rumen clostridium capable of decomposing the filter paper, and the rumen clostridium capable of decomposing the filter paper is DSM 2782. Experiments prove that the bacterial strain improves colon shortening, colon bleeding, excrement character change and colon tissue damage caused by ulcerative colitis modeling, and has the effect of preventing and / or treating ulcerative colitis.

The application discloses a lactobacillus rhamnosus capable of significantly increasing the number of enteric neurons and neuroglial cells and an application thereof, and belongs to the field of microorganisms.The lactobacillus rhamnosus CCFM1360 has good activity, certain acid and alkali resistance and adhesion, can significantly increase the number of enteric neurons and neuroglial cells, repair intestinal barrier function, increase the content of SCFAs in colon contents, increase the number of Treg cells in mesenteric lymph nodes, reduce the expression level of inflammatory factors in colon tissues, reduce the intestinal inflammation level, and relieve the weakened intestinal motility disorder.

The invention discloses application of radix clematidis in development of a medicine for treating gastroesophageal reflux disease. The radix clematidis is used for repairing an esophageal mucosal barrier function, enhancing an esophageal clearing effect and relieving heartburn and acid regurgitation effects; the generation of proinflammatory factors in colon tissues is inhibited, inflammatory cells are reduced, and the expression of related protease is reduced; the traditional Chinese medicine composition is prepared into corresponding forms of capsules, pills, powder, tablets, granules, oral liquid and injection, can replace surgical operation treatment, is not easy to grasp in symptoms, does not cause wounds, is not ideal in operation effect on part of patients, does not cause postoperative complications such as stenosis and obstruction, is good in curative effect, can inhibit PI3K / AKT expression, and can be used for treating various diseases. Therefore, the effect of relieving gastroesophageal reflux is achieved.

The invention belongs to the field of analytical chemistry, and provides a method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry, differentiated pretreatment schemes are designed aiming at different biological matrixes such as excrement, serum, colon tissue and NCM460 inflammatory cells through a liquid chromatography-tandem mass spectrometry technology, matrix interference is effectively eliminated, and the method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry is provided. A quantitative analysis method with high sensitivity and high selectivity is established; the method is successfully applied to an ulcerative colitis (UC) rat model and a lipopolysaccharide (LPS)-induced NCM460 inflammation model, and a technical means is provided for revealing a metabolic regulation mechanism of medicine intervention on UC; the method solves the technical problem that various metabolites in a tryptophan metabolic pathway are difficult to detect in the prior art, is suitable for metabolic mechanism research, drug intervention effect evaluation and large-scale detection of clinical samples of inflammatory bowel diseases such as UC, and provides a technical basis for systematic research of a tryptophan metabolic network.

The invention discloses application of ethyl sulfate in preparation of a medicine for preventing and / or treating inflammatory bowel diseases, and belongs to the technical field of medicines. The invention finds that ethyl sulfate has the effect of preventing and / or treating inflammatory bowel disease for the first time: the ethyl sulfate can obviously improve the survival index of an inflammatory bowel disease model mouse and reduce the disease activity index; the symptoms of weight loss, stool character, inflammation-related diarrhea and bloody stool are relieved; the length of colon tissue is improved, and the size and number of tumors in colorectum are reduced; the pharmaceutical composition has the effects of inhibiting the level of proinflammatory cytokines (TNF-alpha, IL-8, IL-1beta and IL-6), recovering the level of anti-inflammatory cytokines (IL-10 and INF-gamma), inhibiting the enzymatic activity of MPO and MDA and improving the enzymatic activity of SOD and GSH-Px, so that the inflammatory reaction and oxidative stress reaction in the inflammatory bowel disease microenvironment are improved, and the pharmaceutical composition has the pharmacological action of preventing and / or treating the inflammatory bowel disease.

The invention discloses an application of a prunus tomentosa seed alcohol extract in preparation of an anti-colitis medicine. In the invention, the prunus tomentosa seed alcohol extract with the function of resisting colitis is obtained by reflux extraction of prunus tomentosa seeds with 70% ethanol, and has a remarkable inhibition effect on dextran sodium sulfate induced mouse colitis; wherein the weight loss of the mouse is slowed down, the DAI score of the mouse is reduced, the injury of the colon tissue of the mouse is relieved, the content of IL-6, IL-1beta, TNF-alpha and MDA in the colon tissue and serum of the mouse is reduced, and the activity of CAT and SOD in the colon tissue and serum of the mouse is enhanced. The prunus tomentosa seed alcohol extract inhibits the activation of ROS-mediated MAPKs and NF-kappa B pathways, and further inhibits the excessive secretion of proinflammatory mediators NO and PGE2 and proinflammatory cytokines TNF-alpha, IL-6 and IL-1beta in lipopolysaccharide-induced RAW264.7 cells. Therefore, the prunus tomentosa seed alcohol extract has a remarkable anti-inflammatory effect in vivo and in vitro, and can be used for treating colitis.

The invention discloses application of a waxberry seed alcohol extract in preparation of a medicine for treating colitis. The waxberry seed alcohol extract inhibits the generation of LPS-induced proinflammatory mediators (NO) and proinflammatory cytokines (TNF-alpha, IL-6 and IL-1beta) under the condition of no cytotoxicity; the waxberry seed alcohol extract inhibits the expression of the protein of LPS-induced pro-inflammatory mediator enzymes (iNOS and COX-2); the waxberry seed alcohol extract not only inhibits nuclear transfer of NF-kappa B by reducing phosphorylation and degradation of I kappa B alpha, but also inhibits phosphorylation of MPAKs (ERK, p38 and JNK); animal experiments prove that the waxberry seed alcohol extract shortens mouse colon, reduces mouse DAI score, alleviates mouse colon tissue damage, reduces the content of IL-6, IL-1beta, TNF-alpha and MDA in mouse colon tissue and serum, and enhances the activity of CAT and SOD in mouse colon tissue and serum. Therefore, the waxberry seed alcohol extract has a remarkable anti-inflammatory effect in vivo and in vitro, and can be used for treating colitis.